Symbols

BCDA

Biocardia·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Bullish Abandoned Baby

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BCDA

Biocardia, Inc.

A clinical-stage biotechnology company developing innovative cardiovascular therapies, including cell-based treatments for heart failure

Industry

Biological Technology

Established Date

01/12/1994

Listing Date

08/02/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.biocardia.com

Security Type

Common stock

Office address

320 Soquel Way, Sunnyvale, California 94085

Business

Introduction

Biocardia, Inc., was incorporated in Delaware on January 12, 1994. The company is a clinical-stage company developing cells and cell-derived therapies for cardiovascular and pulmonary diseases. Its CardiAMP autologous mononuclear cell therapy platform is advancing for ischemic heart failure and refractory angina, while its allogeneic mesenchymal stem cell therapy platform is being developed for ischemic inflammatory heart failure.

Company Financials

EPS

BCDA has released its 2025 Q4 earnings. EPS was reported at 0, versus the expected -0.17, beating expectations. The chart below visualizes how BCDA has performed over recent quarters, highlighting trends in earnings surprises.